20 articles
New computational advances help identify which tumor peptides trigger immune responses, potentially revolutionizing personalized cancer therapy.
Longevity experts endorse short CGM trials for non-diabetics, but RCT evidence remains thin. Here's what the data actually shows.
Expert reviews compare top CGMs for longevity use, but evidence for healthy adults remains limited. Here's what you need to know.
Longevity experts endorse CGMs for metabolic optimization, but RCT evidence in non-diabetics is still thin.
A landmark review reveals how sustained glucocorticoid exposure drives aging biology — and what can be done about it.
A head-to-head review of 10 CGM devices for healthy adults, weighing real-world accuracy data against limited longevity evidence.
Dexcom G7 tops expert picks for metabolic biohacking, but evidence for non-diabetics remains mixed. Here's what the data says.
Six leading CGM platforms compared on accuracy, evidence quality, and longevity claims — most fall short of the hype.
Top longevity doctors endorse CGMs for healthy adults, but evidence is mixed. Here's what the 2026 device reviews reveal.
A Dana-Farber review maps the path for personalized cancer vaccines — pinpointing which tumors, timing, and combination strategies will matter most.
Continuous glucose monitors are popular in biohacking circles, but direct evidence linking CGM use to extended lifespan remains thin.
A landmark review reveals how diet, gut bacteria, and their metabolites determine the success of immune checkpoint blockade cancer therapy.
A landmark AHA scientific statement tackles inconsistent cardiovascular safety reporting in oncology trials with a unified framework.
A Cochrane review of two RCTs finds very low-certainty evidence that IGF-1 neither prevents nor worsens retinopathy of prematurity in extremely preterm infants.
A new review links adult cholestasis to pediatric genetic syndromes, opening doors to targeted therapies including novel bile acid transport inhibitors.
New review reveals how advanced genomics tools are revolutionizing cancer diagnosis and therapy development.
Expert reviews of top CGM platforms reveal genuine metabolic insights — but no proof they extend lifespan in healthy adults.
New research reveals how tumors might hijack sympathetic nervous system signals to boost their metabolism and proliferation.
Independent testing reveals rampant quality failures in NMN, NR, and NAD+ supplements. Know what to look for before buying.
A translational review outlines how stem cell technologies may finally make hepatocyte-based liver therapies clinically viable.
